Samsung Biologics Co Ltd
KRX:207940
Samsung Biologics Co Ltd
Total Receivables
Samsung Biologics Co Ltd
Total Receivables Peer Comparison
Competitive Total Receivables Analysis
Latest Figures & CAGR of Competitors
Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Samsung Biologics Co Ltd
KRX:207940
|
Total Receivables
₩760.4B
|
CAGR 3-Years
30%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
P
|
Peptron Inc
KOSDAQ:087010
|
Total Receivables
₩823.9m
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Total Receivables
₩122.6B
|
CAGR 3-Years
53%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Total Receivables
₩3.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Total Receivables
₩68.3B
|
CAGR 3-Years
57%
|
CAGR 5-Years
11%
|
CAGR 10-Years
120%
|
C
|
Cellivery Therapeutics Inc
KOSDAQ:268600
|
Total Receivables
₩6.8B
|
CAGR 3-Years
131%
|
CAGR 5-Years
84%
|
CAGR 10-Years
N/A
|
See Also
What is Samsung Biologics Co Ltd's Total Receivables?
Total Receivables
760.4B
KRW
Based on the financial report for Mar 31, 2024, Samsung Biologics Co Ltd's Total Receivables amounts to 760.4B KRW.
What is Samsung Biologics Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 5Y
50%
Over the last year, the Total Receivables growth was 19%. The average annual Total Receivables growth rates for Samsung Biologics Co Ltd have been 30% over the past three years , 50% over the past five years .